NCT04402996

Brief Summary

Metrnl has proven to be an inflammatory-related immunoregulatory cytokine and shown to play a role in the pathogenesis of human inflammatory diseases. Metrnl is highly expressed from the oral mucosa to the esophagus. Periodontitis is a chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. The authors think that Metrnl may play a role in the periodontitis. The aim of this study is to compare the Metrnl, IL-1β, and IL-10 levels of healthy and periodontitis individuals.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 19, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 27, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

September 23, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 3, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 3, 2021

Completed
Last Updated

April 29, 2024

Status Verified

April 1, 2024

Enrollment Period

5 months

First QC Date

May 19, 2020

Last Update Submit

April 25, 2024

Conditions

Keywords

Meteorin-like

Outcome Measures

Primary Outcomes (3)

  • IL-1β

    saliva and serum levels

    through study completion, an average of 6 months

  • Metrnl

    saliva and serum levels

    through study completion, an average of 6 months

  • IL-10 levels

    saliva and serum levels

    through study completion, an average of 6 months

Secondary Outcomes (3)

  • Plaque Index

    up to 20 weeks

  • Probing Depth

    up to 20 weeks

  • Bleeding on Probe

    up to 20 weeks

Study Arms (3)

Healthy

Individuals with Periodontally Healthy

Other: SalivaOther: gingival crevicular fluid

Gingivitis

Individuals with Gingival Inflammation

Other: SalivaOther: gingival crevicular fluid

Periodontitis

Individuals with Periodontitis

Other: SalivaOther: gingival crevicular fluid

Interventions

SalivaOTHER

individuals' saliva samples will be collected and transferred to eppendorf tubes. Until biochemical analysis is carried out will be stored in -80ºC.

Also known as: sampling
GingivitisHealthyPeriodontitis

GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes. Until biochemical analysis is carried out will be stored in -80ºC.

Also known as: sampling
GingivitisHealthyPeriodontitis

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Individuals will be divided into three different groups, about 20-25 people in each group.

You may qualify if:

  • systemically healthy
  • individuals who does not have a disease under treatment,
  • individuals without regular systemic medication

You may not qualify if:

  • smoking
  • receiving periodontal treatment in the last 6 months
  • pregnancy
  • menopausal or menstrual period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ebru Sağlam

Istanbul, Eyalet/Yerleşke, 34668, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

Gingival Crevicular Fluid and Saliva

MeSH Terms

Conditions

PeriodontitisGingivitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic DiseasesInfectionsGingival Diseases

Study Officials

  • Ayşe Toraman, Dr.

    Saglik Bilimleri Universitesi

    STUDY CHAIR
  • Serhat Köseoğlu, assoc prof

    Saglik Bilimleri Universitesi

    STUDY CHAIR
  • Mehmet Sağlam, assoc prof

    Izmir Katip Celebi University

    STUDY CHAIR
  • Levent Savran, PhD

    Izmir Katip Celebi University

    STUDY CHAIR
  • Ebru Sağlam, Dr

    Saglik Bilimleri Universitesi

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator,Health Sciences University, Dentistry Faculty

Study Record Dates

First Submitted

May 19, 2020

First Posted

May 27, 2020

Study Start

September 23, 2020

Primary Completion

March 3, 2021

Study Completion

March 3, 2021

Last Updated

April 29, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations